Recursion Pharmaceuticals (NASDAQ:RXRX) Stock: Insider Blake Borgeson Sells 40,000 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 40,000 shares of the firm’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $3.88, for a total transaction of $155,200.00. Following the transaction, the director owned 6,068,287 shares in the company, valued at $23,544,953.56. This represents a 0.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, October 6th, Blake Borgeson sold 50,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $4.84, for a total value of $242,000.00.
• On Tuesday, September 1st, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.34, for a total value of $100,200.00.

Recursion Pharmaceuticals Trading Down 9.8%

Shares of Recursion Pharmaceuticals stock opened at $3.50 on Friday. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of -3.89 and a beta of 1.15. Recursion Pharmaceuticals, Inc. has a 1-year low of $2.77 and a 1-year high of $5.24. The firm has a fifty day simple moving average of $3.77 and a 200-day simple moving average of $3.52.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Monday, November 2nd. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.22). The company had revenue of $18.55 million during the quarter, compared to analysts’ expectations of $14.81 million. Recursion Pharmaceuticals had a negative net margin of 697.15% and a negative return on equity of 47.85%. During the same period in the prior year, the company earned ($0.36) earnings per share. As a group, research analysts predict that Recursion Pharmaceuticals, Inc. will post -0.93 earnings per share for the current year.

Recursion Pharmaceuticals News Roundup

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: Recursion reported Q3 revenue of $18.55 million, above analysts’ $14.81 million estimate, while its loss of $0.22 per share matched expectations. The company also highlighted promising clinical data for REC-4881 and REC-1245 and said disciplined spending extends its cash runway into 2029. RXRX Q3 Earnings Call Highlights Clinical Progress and Cash Runway
• Positive Sentiment: Fred Hassan is taking the chairmanship following a Phase 2 win, adding an experienced leader as the company advances its drug pipeline. Recursion Pharmaceuticals Puts Fred Hassan In The Chair After Phase 2 Win
• Neutral Sentiment: Bank of America Securities maintained a Hold rating, indicating a cautious stance rather than a new positive or negative call. Bank of America Securities Remains a Hold on Recursion Pharmaceuticals
• Negative Sentiment: The anticipated FDA discussion about REC-4881 was inconclusive, with further clarity pushed to year-end. The delay leaves uncertainty around a potential development catalyst. RXRX Earnings: Revenue beats expectations, but FDA discussion on REC-4881 remains inconclusive
• Negative Sentiment: Director Blake Borgeson sold 40,000 shares for $155,200. The sale was made under a pre-arranged Rule 10b5-1 plan, and he continues to hold more than 6 million shares, which may temper the signal. Recursion Pharmaceuticals Director Sells $155,200 in Stock

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of large investors have recently bought and sold shares of RXRX. Jacobi Capital Management LLC acquired a new stake in Recursion Pharmaceuticals in the 3rd quarter valued at about $31,000. Fulcrum Asset Management LLP acquired a new stake in Recursion Pharmaceuticals during the 3rd quarter worth $434,000. Commonwealth Equity Services LLC increased its holdings in Recursion Pharmaceuticals by 23.3% in the third quarter. Commonwealth Equity Services LLC now owns 359,957 shares of the company’s stock valued at $1,487,000 after purchasing an additional 68,018 shares during the last quarter. Kestra Private Wealth Services LLC bought a new stake in shares of Recursion Pharmaceuticals in the 3rd quarter valued at about $58,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Recursion Pharmaceuticals in the third quarter valued at approximately $113,000. 89.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on RXRX shares. Wall Street Zen raised shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, October 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Thursday, October 15th. Morgan Stanley set a $5.90 price objective on shares of Recursion Pharmaceuticals in a report on Friday, October 16th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Monday, October 19th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $8.18.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company’s platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.

Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.